论文部分内容阅读
在发达国家中,由于人口老化和其他心血管疾病治疗的改进,心力衰竭(HF)发病的增加,已成为人们健康的主要问题。强心甙及拟交感药仍是多年来用于强心疗法的两类药物。但由于强心甙可诱发心律失常及慢性依赖性,拟交感药则不能口服,因而限制了它们的使用。在过去的10年里,为更有效地治疗充血性心力衰竭(CHF),发展了大量新型强心药,包括氨力农、米力农、硫马唑、依诺昔酮、匹罗昔酮、伊马唑坦、Cl-930、indolidan和匹莫苯。所有这些药物均主要是通过选择性地抑制心肌上3′、5′-环磷酸腺苷磷酸二酯酶Ⅲ(cAMP PDE Ⅲ)而发挥作用。但对这些新型的非甙、非儿茶酚胺类强心药的作用众说纷纭。促使心率加快和导致心律失常是这类药物的主要不良反应。尽管这些药物肯定能改善疾病时血流动力学状况和心脏功
In developed countries, the increase in the incidence of heart failure (HF) has become a major health problem in the population as a result of the aging population and the improvement in the treatment of other cardiovascular diseases. Cardiac glycosides and sympathomimetics are still two types of drugs that have been used in cardiac therapy for many years. However, cardiac glycosides can induce arrhythmia and chronic dependence, sympathetic drugs can not be orally, thus limiting their use. In the past decade, a number of new cardiotonics have been developed to more effectively treat congestive heart failure (CHF), including amrinone, milrinone, thremazole, enoximone, , Immazolam, Cl-930, indolidan and pimobendan. All of these drugs work primarily by selectively inhibiting 3 ’, 5’-cAMP PDE III in the myocardium. However, the role of these new non-glycosidic, non-catecholamine cardix drugs are widely divergent. Promote faster heart rate and lead to arrhythmia is the main adverse drug reactions. Although these drugs certainly improve disease hemodynamics and heart work